Please select your page
  • Slide
  • Slide
  • Slide

Press releases

04/09/2015 Cerenis Therapeutics announces the publication of positive preclinical data in the world-renowned scientific journal PLOS ONEacrobat bleu
25/08/2015 Results for the first half of 2015acrobat bleu
21/07/2015 Revenue and cash position for H1 2015acrobat bleu
15/07/2015 Cerenis Therapeutics announces the results of the LOCATION studyacrobat bleu
09/06/2015 Cerenis Therapeutics announces new Board membersacrobat bleu
26/05/2015 CERENIS THERAPEUTICS featured prominently at the INTERNATIONAL SYMPOSIUM ON ATHEROSCLEROSIS (IAS) acrobat bleu
13/05/2015 Cash position and revenue for Q1 2015acrobat bleu
25/03/2015 Outstanding success of Cerenis Therapeutics’ IPO with €53.4 million raised on Euronext Parisacrobat bleu
12/03/2015 CERENIS THERAPEUTICS launches its IPO on the Euronext regulated market in Parisacrobat bleu
09/02/2015 CERENIS THERAPEUTICS announces the appointment of a new Director of Clinical Research and new members to the Board acrobat bleu
03/09/2014 CERENIS THERAPEUTICS receives EMA Orphan Drug Designations for CER-001 for the treatment of ApoA-I and ABCA-1 deficiencies acrobat bleu
03/09/2014 CERENIS THERAPEUTICS appoints R. Pasternak as Chairman of Cerenis Board September 3, 2014 acrobat bleu
02/06/2014 CERENIS THERAPEUTICS reports two positive Phase II Studies for HDL mimetic CER-001 at EA acrobat bleu

Contact

Cerenis Therapeutics Holding SA
33-43 av. Georges Pompidou – Bât. D2
31130 Balma – France
Tel. +33 5 62 24 97 06
Fax +33 5 61 57 34 12

Email: info@cerenis.com

 Cerenis Therapeutics Inc
PO Box 861
Lakeland, MI 48143
USA

© 2019 ® Cerenis